Godrej Agrovet (GODREJAGRO) Q4 24/25 earnings summary

Executive summary

• Achieved record standalone profitability in FY 2025, with consolidated EBITDA up 11.6% to ₹845 crore and PAT up 4.5% to ₹386 crore, driven by strong crop protection and vegetable oil segments, and margin expansion in animal feed.

• FY25 consolidated revenues declined 1.9% year-over-year to ₹9,383 crore, while Q4 FY25 revenues were flat year-over-year at ₹2,134 crore.

• Board approved audited financial results for FY25 with unmodified audit opinions; final dividend of Rs. 11 per share recommended, subject to shareholder approval.

• Recognized for climate action and sustainability by CII, ALA, and other organizations, with 81% energy from renewables and water positivity.

Financial highlights

• FY25 EBITDA margin improved to 9.0% from 7.9% year-over-year; PAT margin rose to 4.1% from 3.9%.

• Consolidated net profit after tax for FY25 was Rs. 403.37 crore, up from Rs. 359.45 crore in FY24; basic EPS at Rs. 22.35.

• Cash generated from operations for FY25 was Rs. 1,115.88 crore, with net cash from operating activities at Rs. 969.34 crore.

• Non-recurring items and Astec losses impacted reported results; adjusted figures show stronger profitability.

Outlook and guidance

• FY 2026 guidance targets 15%-18% top-line and 16%-18% bottom-line growth, mainly volume-driven.

• Astec LifeSciences CDMO business guided for 35% year-on-year growth for the next couple of years.

• Crop protection margins expected to normalize to 30%+ EBIT in FY 2026, with 25%-30% targeted over the next three years.

• Board expects to complete the acquisition of the remaining 48.06% stake in Creamline Dairy Products Limited by September 30, 2025.